2015
Integrated genomic characterization of IDH1-mutant glioma malignant progression
Bai H, Harmancı AS, Erson-Omay EZ, Li J, Coşkun S, Simon M, Krischek B, Özduman K, Omay SB, Sorensen EA, Turcan Ş, Bakırcığlu M, Carrión-Grant G, Murray PB, Clark VE, Ercan-Sencicek AG, Knight J, Sencar L, Altınok S, Kaulen LD, Gülez B, Timmer M, Schramm J, Mishra-Gorur K, Henegariu O, Moliterno J, Louvi A, Chan TA, Tannheimer SL, Pamir MN, Vortmeyer AO, Bilguvar K, Yasuno K, Günel M. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nature Genetics 2015, 48: 59-66. PMID: 26618343, PMCID: PMC4829945, DOI: 10.1038/ng.3457.Peer-Reviewed Original ResearchConceptsDevelopmental transcription factorsActivation of MYCMalignant progressionGenomic approachesPI3K pathwayGlioma malignant progressionEpigenetic silencingIDH1 mutant gliomasTranscription factorsIntegrated genomic characterizationGenomic characterizationRTK-RASOncogenic pathwaysK pathwayClonal expansionPathwaySilencingMYCProgressionSomatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis
Erson-Omay EZ, Çağlayan AO, Schultz N, Weinhold N, Omay SB, Özduman K, Köksal Y, Li J, Serin Harmancı A, Clark V, Carrión-Grant G, Baranoski J, Çağlar C, Barak T, Coşkun S, Baran B, Köse D, Sun J, Bakırcıoğlu M, Moliterno Günel J, Pamir MN, Mishra-Gorur K, Bilguvar K, Yasuno K, Vortmeyer A, Huttner AJ, Sander C, Günel M. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro-Oncology 2015, 17: 1356-1364. PMID: 25740784, PMCID: PMC4578578, DOI: 10.1093/neuonc/nov027.Peer-Reviewed Original ResearchConceptsHigh-grade gliomasSomatic POLE mutationsPOLE mutationsMalignant high-grade gliomasLonger progression-free survivalProgression-free survivalSomatic mutationsOverall survivalPediatric patientsBetter prognosisClinical featuresImproved prognosisClinical behaviorImmune cellsBizarre cellsAggressive formGlioblastoma multiformeDisease pathophysiologyMolecular subgroupsHomozygous germline mutationGermline mutationsPrognosisGlioma subtypesComprehensive genomic analysisDistinct subgroups
2012
Low-Grade Gliomas When and How to Treat
Omay SB, Piepmeier JM, Knisely JP. Low-Grade Gliomas When and How to Treat. Hematology/Oncology Clinics Of North America 2012, 26: 797-809. PMID: 22794284, DOI: 10.1016/j.hoc.2012.05.001.Peer-Reviewed Original ResearchConceptsSurgical resectionLow-grade gliomasPatient-specific variablesSame imaging techniqueRadiotherapeutic managementUncommon tumorClinical trialsOperative techniqueHistopathologic characterizationGrade gliomasOptimal managementAdditional studiesGliomasResectionAdequate samplesImaging techniquesPatientsPrognosisManagementTumorsTrials
2009
Current concepts and newer developments in the treatment of malignant gliomas
Omay S, Vogelbaum M. Current concepts and newer developments in the treatment of malignant gliomas. Indian Journal Of Cancer 2009, 46: 88-95. PMID: 19346642, DOI: 10.4103/0019-509x.49146.Peer-Reviewed Original ResearchConceptsMalignant gliomasPrimary malignant brain tumorCancer-related disabilityMalignant glioma patientsStandard treatment modalityGlioma cell biologyMalignant brain tumorsNew treatment strategiesTreatment modalitiesChallenging tumorsSystemic administrationNovel therapiesTreatment strategiesAdult cancersGlioma patientsRadiation therapyBrain tumorsTherapyTumorsGliomasCurrent conceptsChemotherapyPatientsSurgeryGreater understanding